Standard BioTools Inc. CEO Michael Egholm will present at the J.P. Morgan Healthcare Conference on January 16, 2024.
Quiver AI Summary
Standard BioTools Inc. announced that its President and CEO, Dr. Michael Egholm, will present at the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2024, with his presentation scheduled for January 16 at 9:45 a.m. PT. The event will take place at the Westin St. Francis Hotel in San Francisco, and a live audio webcast will be available for interested investors on the company's website. Standard BioTools, formerly Fluidigm Corporation, offers a range of next-generation technologies to aid biomedical research and improve patient outcomes, focusing on key areas such as oncology and immunotherapy.
Potential Positives
- Participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference showcases the company's leadership and commitment to advancing healthcare solutions.
- Dr. Michael Egholm's presentation indicates significant investor engagement opportunities to highlight the company's innovative technologies and market position.
- The live audio webcast and archived recording of the presentation demonstrate transparency and provide broader access to stakeholders interested in the company's developments.
Potential Negatives
- None
FAQ
When will Standard BioTools present at the J.P. Morgan Healthcare Conference?
Standard BioTools will present on January 16th, 2024, at 9:45 a.m. PT.
Where can I watch the Standard BioTools presentation live?
A live audio webcast will be available on the Investor Relations page of Standard BioTools' website.
What technologies does Standard BioTools focus on?
Standard BioTools specializes in SomaScan, mass cytometry, and microfluidics technologies for biomedical research.
Who is the CEO of Standard BioTools?
The President and CEO of Standard BioTools is Michael Egholm, PhD.
What are the main research areas of Standard BioTools?
Standard BioTools focuses on oncology, immunology, and immunotherapy in translational and clinical research.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LAB Insider Trading Activity
$LAB insiders have traded $LAB stock on the open market 15 times in the past 6 months. Of those trades, 15 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LAB stock by insiders over the last 6 months:
- PARTNERS MASTER FUND, L.P. CASDIN has traded it 15 times. They made 15 purchases, buying 7,294,970 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LAB Hedge Fund Activity
We have seen 59 institutional investors add shares of $LAB stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INDABA CAPITAL MANAGEMENT, L.P. removed 7,363,064 shares (-100.0%) from their portfolio in Q2 2024
- CASDIN CAPITAL, LLC added 7,295,000 shares (+11.4%) to their portfolio in Q3 2024
- HOLLOW BROOK WEALTH MANAGEMENT LLC added 5,532,951 shares (+inf%) to their portfolio in Q3 2024
- ARK INVESTMENT MANAGEMENT LLC removed 3,729,626 shares (-29.4%) from their portfolio in Q3 2024
- MORGAN STANLEY added 2,310,920 shares (+17.9%) to their portfolio in Q3 2024
- SUMITOMO MITSUI TRUST HOLDINGS, INC. added 1,788,780 shares (+20.2%) to their portfolio in Q2 2024
- PARKMAN HEALTHCARE PARTNERS LLC removed 1,670,401 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43 rd Annual J.P. Morgan Healthcare Conference taking place on January 13 th - 16 th at the Westin St. Francis Hotel in San Francisco, CA.
Dr. Egholm’s corporate presentation will be held on January 16 th , 2024, at 9:45 a.m. PT.
A live audio webcast will be available to investors and other interested parties by accessing the Investor Relations page of the Company’s website at Events & Presentations . A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com .
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook ® , LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms .
Patent and License Information: standardbio.com/legal/notices .
Trademarks: standardbio.com/legal/trademarks . Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
